{"id":"W3200553460","doi":"10.1016/j.kint.2021.05.015","title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","year":2021,"lang":"en","type":"article","venue":"Kidney International","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":791,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; Impact; McMaster University; University of Toronto","funders":"Medical Research Council; Chugai Pharmaceutical; EMD Serono; MorphoSys; Astellas Pharma; Idorsia Pharmaceuticals; ZonMw; CSL Behring; National Institute for Health and Care Research; Bristol-Myers Squibb; University of Leicester; Argenx; National Institutes of Health; Société de Néphrologie; Natera; Genentech; Amicus Therapeutics; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Omeros Corporation; Celgene; BioCryst; Prothena; Alnylam Pharmaceuticals; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; InflaRx; Pfizer; Biogen; University Health Network; GlaxoSmithKline; American Society of Nephrology; AstraZeneca; Amgen","keywords":"Guideline; Medicine; Intensive care medicine; Lupus nephritis; Glomerulonephritis; Focal segmental glomerulosclerosis; Nephropathy; Immunology; Disease; Pathology; Internal medicine; Kidney; Diabetes mellitus","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0112387636961169,"score_gpt":0.2881005084737354,"score_spread":0.2768617447776185,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}